help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sklar, C.
Right arrow Articles by Robison, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sklar, C.
Right arrow Articles by Robison, L.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 9 3227-3232
Copyright © 2000 by The Endocrine Society


Original Studies

Abnormalities of the Thyroid in Survivors of Hodgkin’s Disease: Data from the Childhood Cancer Survivor Study1

Charles Sklar, John Whitton, Ann Mertens, Marilyn Stovall, Daniel Green, Neyssa Marina, Brian Greffe, Suzanne Wolden and Leslie Robison

Departments of Pediatrics (C.S.) and Radiation Oncology (S.W.), Memorial Sloan-Kettering Cancer Center, New York, New York 10021; Department of Biostatistics, Fred Hutchinson Cancer Research Center (J.W.), Seattle, Washington 98104; Department of Pediatrics, University of Minnesota (A.M., L.R.), Minneapolis, Minnesota 55455; Department of Radiation Physics, University of Texas, M. D. Anderson Cancer Center (M.S.), Houston, Texas 77030; Department of Pediatrics, Roswell Park Cancer Institute (D.G.), Buffalo, New York 14263; Department of Pediatrics, Stanford University Medical Center (N.M.), Stanford, California 94304; and Department of Pediatrics, Children’s Hospital, University of Colorado Health Sciences Center (B.G.), Denver, Colorado 80218

Address all correspondence and requests for reprints to: Charles Sklar, M.D., Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021. E-mail: sklarc{at}mskcc.org

Treatment for Hodgkin’s disease (HD) is associated with a variety of thyroid abnormalities, including hypothyroidism, hyperthyroidism, and thyroid neoplasms. Due to the small sample size and short follow-up time of most published studies, it has been difficult to appreciate the full extent of the problem and to characterize the interaction between various patient and treatment variables. To overcome these limitations we have assessed thyroid status in 1,791 (959 males) HD survivors from among 13,674 participants in the Childhood Cancer Survivor Study, a cohort of 5-yr survivors of childhood and adolescent cancer diagnosed between 1970 and 1986. Thyroid abnormalities were ascertained as part of a 22-page questionnaire sent to participants. Survivors were a median of 14 yr (range, 2–20 yr) at diagnosis of HD and a median of 30 yr (range, 12–47 yr) at follow-up. Seventy-nine percent of subjects were treated with radiation (median dose of radiation to the thyroid, 3500 cGy; range, 0.37–5500 cGy). Control data were available from 2,808 (1,346 males) sibling controls. Thirty-four percent of the entire cohort has been diagnosed with at least one thyroid abnormality. Hypothyroidism was the most common disturbance, with a relative risk of 17.1 (P < 0.0001) compared to sibling controls. Increasing dose of radiation, older age at diagnosis of HD, and female sex were all independently associated with an increased risk of hypothyroidism. Actuarial risk of hypothyroidism for subjects treated with 4500 cGy or more is 50% at 20 yr from diagnosis. Hyperthyroidism was reported by 5% of survivors, which was 8-fold greater (P < 0.0001) than the incidence reported by the controls. Thyroid dose of 3500 cGy or more was the only risk factor identified for hyperthyroidism. The risk of thyroid nodules was 27 times (P < 0.0001) that in sibling controls. Female sex and radiation dose to the thyroid of 2500 cGy or more were independent risk factors for thyroid nodules. The actuarial risk of a female survivor developing a thyroid nodule is 20% at 20 yr from diagnosis. Thyroid cancer was diagnosed in 20 survivors, which is 18 times the expected rate for the general population. After taking into account the possibility that some of the relative risk estimates may be exaggerated due to ascertainment bias, abnormalities of the thyroid are still extremely common in young adult survivors of childhood HD, particularly among females treated with high doses of radiation to the neck.




This article has been cited by other articles:


Home page
The OncologistHome page
W. Landier and S. Bhatia
Cancer Survivorship: A Pediatric Perspective
Oncologist, November 1, 2008; 13(11): 1181 - 1192.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. Bhatia and L. L. Robison
Cancer Survivorship Research: Opportunities and Future Needs for Expanding the Research Base
Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1551 - 1557.
[Full Text] [PDF]


Home page
PediatricsHome page
K. Wasilewski-Masker, S. C. Kaste, M. M. Hudson, N. Esiashvili, L. A. Mattano, and L. R. Meacham
Bone Mineral Density Deficits in Survivors of Childhood Cancer: Long-term Follow-up Guidelines and Review of the Literature
Pediatrics, March 1, 2008; 121(3): e705 - e713.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. T. Armstrong, C. A. Sklar, M. M. Hudson, and L. L. Robison
Long-Term Health Status Among Survivors of Childhood Cancer: Does Sex Matter?
J. Clin. Oncol., October 1, 2007; 25(28): 4477 - 4489.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
J. K. Hoang, W. K. Lee, M. Lee, D. Johnson, and S. Farrell
US Features of Thyroid Malignancy: Pearls and Pitfalls
RadioGraphics, May 1, 2007; 27(3): 847 - 860.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
J. D. Dickerman
The Late Effects of Childhood Cancer Therapy
Pediatrics, March 1, 2007; 119(3): 554 - 568.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. M.L. Chow, P. C. Nathan, D. C. Hodgson, D. Jenkin, S. Weitzman, R. M. Grant, D. Manson, A. Bross, J. J. Doyle, C. Danjoux, et al.
Survival and Late Effects in Children With Hodgkin's Lymphoma Treated With MOPP/ABV and Low-Dose, Extended-Field Irradiation
J. Clin. Oncol., December 20, 2006; 24(36): 5735 - 5741.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. C. Chung, M. M. Maher, and W. C. Faquin
Case 37-2006 -- A 19-Year-Old Woman with Thyroid Cancer and Lower Gastrointestinal Bleeding
N. Engl. J. Med., November 30, 2006; 355(22): 2349 - 2357.
[Full Text] [PDF]


Home page
Endocr Relat CancerHome page
M Niedziela
Pathogenesis, diagnosis and management of thyroid nodules in children.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 427 - 453.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. L. Metzger, M. M. Hudson, G. W. Somes, R. I. Shorr, C.-S. Li, M. J. Krasin, J. Shelso, C.-H. Pui, and S. C. Howard
White Race As a Risk Factor for Hypothyroidism After Treatment for Pediatric Hodgkin's Lymphoma
J. Clin. Oncol., April 1, 2006; 24(10): 1516 - 1521.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. K. Ng, S. Li, C. Recklitis, D. Neuberg, S. Chakrabarti, B. Silver, and L. Diller
A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue
Ann. Onc., December 1, 2005; 16(12): 1949 - 1955.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. Landier, S. Bhatia, D. A. Eshelman, K. J. Forte, T. Sweeney, A. L. Hester, J. Darling, F. D. Armstrong, J. Blatt, L. S. Constine, et al.
Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-Term Follow-Up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline
J. Clin. Oncol., December 15, 2004; 22(24): 4979 - 4990.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
H K Gleeson and S M Shalet
The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours
Endocr. Relat. Cancer, December 1, 2004; 11(4): 589 - 602.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Ishiguro, Y. Yasuda, Y. Tomita, T. Shinagawa, T. Shimizu, T. Morimoto, K. Hattori, M. Matsumoto, H. Inoue, H. Yabe, et al.
Long-Term Follow-Up of Thyroid Function in Patients Who Received Bone Marrow Transplantation during Childhood and Adolescence
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 5981 - 5986.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
L. B. Kenney, Y. Yasui, P. D. Inskip, S. Hammond, J. P. Neglia, A. C. Mertens, A. T. Meadows, D. Friedman, L. L. Robison, and L. Diller
Breast Cancer after Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Ann Intern Med, October 19, 2004; 141(8): 590 - 597.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
K. C. Oeffinger and M. M. Hudson
Long-term Complications Following Childhood and Adolescent Cancer: Foundations for Providing Risk-based Health Care for Survivors
CA Cancer J Clin, July 1, 2004; 54(4): 208 - 236.
[Abstract] [Full Text] [PDF]


Home page
Ann Fam MedHome page
K. C. Oeffinger, A. C. Mertens, M. M. Hudson, J. G. Gurney, J. Casillas, H. Chen, J. Whitton, M. Yeazel, Y. Yasui, and L. L. Robison
Health Care of Young Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Ann. Fam. Med, January 1, 2004; 2(1): 61 - 70.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Bhatia, Y. Yasui, L. L. Robison, J. M. Birch, M. K. Bogue, L. Diller, C. DeLaat, F. Fossati-Bellani, E. Morgan, O. Oberlin, et al.
High Risk of Subsequent Neoplasms Continues With Extended Follow-Up of Childhood Hodgkin's Disease: Report From the Late Effects Study Group
J. Clin. Oncol., December 1, 2003; 21(23): 4386 - 4394.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. M. van Santen, T. Vulsma, M. G. Dijkgraaf, R. M. E. Blumer, R. Heinen, M. W. M. Jaspers, M. M. Geenen, M. O. Offringa, J. J. M. De Vijlder, and C. van den Bos
No Damaging Effect of Chemotherapy in Addition to Radiotherapy on the Thyroid Axis in Young Adult Survivors of Childhood Cancer
J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3657 - 3663.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. B. Nachman, R. Sposto, P. Herzog, G. S. Gilchrist, S. L. Wolden, J. Thomson, M. E. Kadin, P. Pattengale, P. C. Davis, R. J. Hutchinson, et al.
Randomized Comparison of Low-Dose Involved-Field Radiotherapy and No Radiotherapy for Children With Hodgkin's Disease Who Achieve a Complete Response to Chemotherapy
J. Clin. Oncol., September 15, 2002; 20(18): 3765 - 3771.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Sklar, A. C. Mertens, P. Mitby, G. Occhiogrosso, J. Qin, G. Heller, Y. Yasui, and L. L. Robison
Risk of Disease Recurrence and Second Neoplasms in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3136 - 3141.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pediatric Oncology NursingHome page
P. C. Kolb Smith
The Role of the Primary Care Advanced Practice Nurse in Evaluating and Monitoring Childhood Cancer Survivors for a Second Malignant Neoplasm
Journal of Pediatric Oncology Nursing, May 1, 2002; 19(3): 84 - 96.
[Abstract] [PDF]


Home page
JNCI J Natl Cancer InstHome page
H. L. Howe, P. A. Wingo, M. J. Thun, L. A. G. Ries, H. M. Rosenberg, E. G. Feigal, and B. K. Edwards
Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends
J Natl Cancer Inst, June 6, 2001; 93(11): 824 - 842.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Waxman and K. C. Anderson
History of the Development of Arsenic Derivatives in Cancer Therapy
Oncologist, April 1, 2001; 6(90002): 3 - 10.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society